NMI 300

Drug Profile

NMI 300

Alternative Names: NMI-300

Latest Information Update: 24 Feb 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nemucore Medical Innovations
  • Class Antineoplastics; Gadolinium-containing contrast agents; Platinum complexes; Small molecules; Sphingolipids
  • Mechanism of Action Diagnostic imaging enhancers; DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Ovarian cancer

Most Recent Events

  • 23 Feb 2016 Phase-I clinical trials in Ovarian cancer (Diagnosis) in USA (Parenteral), before January 2016
  • 28 Jan 2016 Phase-I clinical trials in Ovarian cancer (Treatment-resistant) in USA (Parenteral) before January 2016
  • 24 Mar 2014 Preclinical data released by Nemucore medical Innovations
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top